^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NR2F1 overexpression

    i
    Other names: NR2F1, Nuclear Receptor Subfamily 2 Group F Member 1, EAR-3, COUP Transcription Factor 1, COUP Transcription Factor I, V-ErbA-Related Protein 3, TCFCOUP1, COUPTF1, TFCOUP1, ERBAL3, SVP44, EAR3, Transcription Factor COUP 1 (Chicken Ovalbumin Upstream Promoter 1, V-Erb-A Homolog-Like 3), Chicken Ovalbumin Upstream Promoter-Transcription Factor I, Nuclear Receptor Subfamily 2, Group F, Member 1, BBSOAS, BBOAS
    Entrez ID:
    7025
    12ms
    Exosome-delivered NR2F1-AS1 and NR2F1 drive phenotypic transition from dormancy to proliferation in treatment-resistant prostate cancer via stabilizing hormonal receptors. (PubMed, J Nanobiotechnology)
    In prostate cancer, we utilized high-plasticity mouse models and enzalutamide-resistant (ENZ-R) cellular models to elucidate NR2F1 as a key factor in lineage transition and ENZ resistance...Furthermore, HnRNPA2B1 interacts with NR2F1 and NR2F1-AS1, assisting their packaging into exosomes, wherein exosomal NR2F1 and NR2F1-AS1 promote the proliferation of dormant ENZ-R cells. Our works offer novel insights into the reawaking of dormant drug-resistant cancer cells governed by NR2F1 upregulation triggered by exosome-derived NR2F1-AS1 and NR2F1, suggesting therapeutic potential for phenotype reversal.
    Journal
    |
    ER (Estrogen receptor) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • NR2F1-AS1 (NR2F1 Antisense RNA 1)
    |
    NR2F1 overexpression
    |
    Xtandi (enzalutamide)
    2years
    LncRNA NR2F1-AS1 as a potential biomarker for prognosis in cancer patients: meta and bioinformatics analysis. (PubMed, Expert Rev Mol Diagn)
    However, the difference in age (OR = 1.10,95%Cl 0.71-1.71, p = 0.34), gender (OR = 1.26,95%Cl 0.79-2.00, p = 0.34), Lymph node metastasis (OR = 1.44,95%Cl 0.27-7.80, p = 0.67) or larger tumor size (OR = 1.56,95%Cl 0.48-5.08, p = 0.46) was not statistically significant. Upregulation of LncRNA NR2F1-AS1 was associated with poor prognosis and advanced clinicopathologic features of tumor patients.
    Review • Journal
    |
    NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1) • NR2F1-AS1 (NR2F1 Antisense RNA 1)
    |
    NR2F1 overexpression
    3years
    LncRNA NR2F1-AS1 Inhibits the Malignant Properties of Cervical Cancer Cells via Targeting miR-642a-3p/NR2F1 Axis. (PubMed, Rev Invest Clin)
    Rescue assays showed that NR2F1 knockdown or miR-642a-3p overexpression offset NR2F1-AS1 upregulation-induced inhibition on CC cell malignant phenotypes. These findings revealed that NR2F1-AS1 played a tumor suppressor role in CC by mediating the miR-642a-3p/NR2F1 axis.
    Journal
    |
    NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
    |
    NR2F1 overexpression
    over3years
    ZEB1-regulated lnc-Nr2f1 promotes the migration and invasion of lung adenocarcinoma cells. (PubMed, Cancer Lett)
    Lnc-Nr2f1, in turn, promoted Twist2 transcription through direct binding to its genomic DNA region. Collectively, lnc-Nr2f1 was upregulated by ZEB1 and NR2F1, and promoted migration and invasion of lung adenocarcinoma cells via TWIST2 regulation.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    NR2F1 overexpression
    over3years
    Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis. (PubMed, Cell Death Dis)
    These findings demonstrated that hypoxia-induced NR2F1-AS1 expression directly increased NR2F1 levels to promote PC cell proliferation, migration, and invasion by activating AKT/mTOR signaling. Together, these findings suggest that NR2F1-AS1 could be a prospective therapeutic target for PC.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
    |
    HIF1A expression • NR2F1 overexpression
    almost4years
    NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641. (PubMed, J Healthc Eng)
    Hence, NR2F1-AS1 was found to act as an oncogene in breast cancer by suppressing miR-641. We suggested that NR2F1-AS1 could be a potential biomarker for BC diagnosis and therapy.
    Journal
    |
    NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
    |
    NR2F1 overexpression
    4years
    NR2F1-AS1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Competing Endogenous RNA Regulatory Network Constructed by Sponging miRNA-146a-5p/miRNA-877-5p. (PubMed, Front Cell Dev Biol)
    In conclusion, NR2F1-AS1 overexpression was significantly associated with poor prognosis. NR2F1-AS1 functions as an endogenous RNA to construct a novel ceRNA network by competitively binding to miR-146a-5p/miR-877-5p, which may contribute to PDAC pathogenesis and could represent a promising diagnostic biomarker or potential novel therapeutic target in PDAC.
    Journal
    |
    CLTC (Clathrin Heavy Chain) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1) • PGK1 (Phosphoglycerate Kinase 1)
    |
    NR2F1 overexpression
    over4years
    STAT3 activates the transcription of lncRNA NR2F1-AS1 to promote progression of melanoma via regulating miR-493-5p/GOLM1 axis. (PubMed, J Gene Med)
    Our findings demonstrate a key role for NR2F1-AS1 in melanoma progression via targeting miR-493-5p/GOLM1 axis.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • NR2F1 (Nuclear Receptor Subfamily 2 Group F Member 1)
    |
    NR2F1 overexpression